Allerspray: medical device for the treatment of allergic rhinitis


ALLERSPRAY is a  medical device  specifically designed to form an osmotic, stable, and non-irritating barrier against environmental allergens and contaminants. This unique formulation includes a blend of glycerol, solagum, tannin-rich plant extracts, and food-grade preservatives, ensuring a high-quality product that is both effective and safe for use.


Clinical trial

Randomized, double-blind, placebo-controlled trial

Population

This product is intended for adult use

Indication

Used in adults for the symptomatic treatment of seasonal and intermitent mild-to-moderate allergic rhinitis.

ClaimsClinical studyProduct Details

Claims

  • Protective barrier effect against allergens
  • Reduction of nasal symptoms such as nasal congestion, sneezing, nasal irritation andrhinorrhea within 7 days
  • Reduced eye symptoms such as redness, dehydration and burning within 7 days
  • Improvement in quality of life from the reduction of both nasal and ocular symptoms
  • Reduced need for allergic rhinitis medication medication 
  • Prevent secondary infection and progression to a severe, chronic form 
  • Improved patient well-being and sleep quality

Mode of Action

  • Protective Barrier: Establishes a filmogenic shield on the nasal mucosa, preventing irritants from triggering allergic reactions.
  • Mechanical Cleaning: Utilizes osmotic activity to remove contaminants, reducing inflammation and symptoms.
  • Cellular Repair: Promotes healing and regeneration of the nasal mucosa for sustained relief.

Clinical study


A randomized, double-blind clinical trial highlighted its effectiveness in reducing nasal congestion and irritation, leading to a noticeable improvement in quality of life. The trial also showed significant reductions in total nasal and ocular symptoms within weeks.

See full publication (PDF)

TYPE OF TRIAL: Randomized, double-blind clinical trial against placebo | 3 weeks
PATIENTS: N=51 | Test product = 33 ; Comparator = 15
INCLUSION: Positive skin prick test for allergens and positive basophil count (>10 eosinophils/hpf)

Main results :

TOTAL NASAL SYMPTOMS

  • 38 % reduction in total nasal symptoms within 1 week
  • 58 % reduction in total nasal symptoms within 2 weeks
  • 73 % reduction in total nasal symptoms within 3 weeks

 

TOTAL OCULAR SYMPTOMS

  • 38 % reduction in total ocular symptoms within 1 week
  • 55 % reduction in total ocular symptoms within 2 weeks
  • 64 % reduction in total ocular symptoms within 3 weeks

 

OTHER PARAMETERS

  • 50 % improvement in RQLQ score (Rhinoconjunctivitis Quality of Life Questionnaire)
  • Rescue medicine score : 80 % for placebo group vs 29 % for test group
  • Reduction in eosinophil count : 15 % for placebo group vs 68 % for test group
  • 68 % reduction of allergic activity within 3 week


Product Details


  • Indication: Used in adults for the symptomatic treatment of seasonal and intermitent mild-to-moderate allergic rhinitis.
  • Composition: glycerol, Allercyanidin (extracts from Camellia sinensis, Curcuma longa, Panax ginseng, Urtica dioica), with EO of Citrus limonum.
  • Presentation: 15ml nasal spray, approximately 125 sprays.
  • Class: MDR Class IIa.
  • Usage: 3 sprays in each nostril, 3 times a day. Treatment duration : 3 weeks
  • Precautions: Topical use only. Keep out of reach of children.
  • Exclusions : ALLERSPRAY should not be used in patients who have undergone major surgery on the nasal septum or who have nasal infections requiring specific treatment. The product is contraindicated in patients suffering from bronchopneumopathy, nasal polyps, severe respiratory conditions such as asthma, and in cases of severe chronic rhinitis. It is also not recommended for patients undergoing long-term treatment with antihistamines or immunosuppressants.
  • Age: Suitable for adults 18 and over.
  • Storage: Store below 25°C.
  • Manufacturer: VITROBIO, France.
  • Product Code: AAG.